Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous. Its lead product candidate is VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. VCN-01 has completed a successful Phase IIb clinical trial in first-line metastatic pancreatic cancer patients treated with gemcitabine-nab-paclitaxel standard-of-care chemotherapy.
Back to dashboard
Company Information
About this company
Key people
Jeffrey J. Kraws
Independent Chairman of the Board
Steven A. Shallcross
Chief Executive Officer, Chief Financial Officer and Director
John Monahan
Independent Director
Jeffrey Alan Wolf
Independent Director
Click to see more
Key facts
- Shares in issue45.92m
- EPICTOVX
- ISINUS87164U5083
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$7.64m
- Employees15
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.